23
Feb
Feb
US Health Experts Vote in Favor of Approving New Obesity Drug
An advisory panel of health experts to FDA urged approval of a new obesity drug – Qnexa. The panel voted 20-2 that the FDA should allow Qnexa on the market, saying the latest overall benefit-risk assessment supported its approval.
The drug, made by California-based biotech firm Vivus, is the first obesity drug submitted to the FDA in more than a decade.
Qnexa combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can…
